We are live on ! Find out more
ADIM

Alpha DNA Investment Management Portfolio holdings

AUM $8.98M
1-Year Est. Return 26.05%
This Fund
S&P 500
This Quarter Est. Return
+4.28%
1 Year Est. Return
+26.05%
3 Year Est. Return
+134.39%
5 Year Est. Return
10 Year Est. Return
AUM
$257M
AUM Growth
-$13.3M
Cap. Flow
-$15.3M
Cap. Flow %
-5.95%
Top 10 Hldgs %
43.17%
Holding
259
New
67
Increased
65
Reduced
68
Closed
57

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$2.62M
2
MCD icon
McDonald's
MCD
+$2.54M
3
MDLZ icon
Mondelez International
MDLZ
+$2.52M
4
CI icon
Cigna
CI
+$2.32M
5
JPM icon
JPMorgan Chase
JPM
+$2.18M

Sector Composition

Rank Sector Weight
1 Technology 15.39%
2 Financials 13.15%
3 Healthcare 9.82%
4 Consumer Discretionary 6.3%
5 Industrials 5.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KRYS icon
126
Krystal Biotech
KRYS
$9.77B
$470K 0.18%
2,558
-413
-14% -$69.3K
NUE icon
127
Nucor
NUE
$62.2B
$465K 0.18%
2,941
+684
+30% +$119K
MNDY icon
128
monday.com
MNDY
$3.68B
$462K 0.18%
1,920
-742
-28% -$156K
OSK icon
129
Oshkosh
OSK
$9.63B
$458K 0.18%
+4,231
New +$489K
LYFT icon
130
Lyft
LYFT
$6.7B
$456K 0.18%
+32,371
New +$526K
ARDX icon
131
Ardelyx
ARDX
$997M
$456K 0.18%
+61,536
New +$433K
DY icon
132
Dycom Industries
DY
$12.2B
$452K 0.18%
+2,677
New +$418K
ADMA icon
133
ADMA Biologics
ADMA
$2.21B
$450K 0.17%
40,277
-51,347
-56% -$431K
JAMF
134
DELISTED
Jamf
JAMF
$449K 0.17%
+27,209
New +$476K
ONTO icon
135
Onto Innovation
ONTO
$15.3B
$449K 0.17%
+2,044
New +$422K
HALO icon
136
Halozyme
HALO
$11.7B
$444K 0.17%
8,476
+1,800
+27% +$78.9K
RXST icon
137
RxSight
RXST
$283M
$442K 0.17%
7,340
-4,442
-38% -$254K
CSTL icon
138
Castle Biosciences
CSTL
$997M
$436K 0.17%
20,038
-3,002
-13% -$66.9K
MPC icon
139
Marathon Petroleum
MPC
$93.5B
$432K 0.17%
2,491
+554
+29% +$103K
MTH icon
140
Meritage Homes
MTH
$4.81B
$432K 0.17%
5,334
+1,250
+31% +$105K
ARW icon
141
Arrow Electronics
ARW
$10.5B
$428K 0.17%
3,547
+829
+31% +$106K
SMCI icon
142
Super Micro Computer
SMCI
$20.3B
$428K 0.17%
5,220
-3,510
-40% -$300K
UPWK icon
143
Upwork
UPWK
$1.05B
$427K 0.17%
39,694
-1,985
-5% -$22.5K
NRIX icon
144
Nurix Therapeutics
NRIX
$2.73B
$427K 0.17%
+20,440
New +$318K
CPAY icon
145
Corpay
CPAY
$26.7B
$426K 0.17%
1,598
+344
+27% +$97.4K
TREX icon
146
Trex
TREX
$5.03B
$425K 0.17%
5,734
+505
+10% +$44.2K
URI icon
147
United Rentals
URI
$71.5B
$418K 0.16%
647
+139
+27% +$92.4K
PCTY icon
148
Paylocity
PCTY
$7.75B
$418K 0.16%
+3,172
New +$491K
BPMC
149
DELISTED
Blueprint Medicines
BPMC
$418K 0.16%
+3,879
New +$388K
LEA icon
150
Lear
LEA
$8.15B
$418K 0.16%
3,660
+928
+34% +$119K

Similar funds

Alpha DNA Investment Management's Q2 2024 Portfolio in Review

As of Q2 2024, Alpha DNA Investment Management held 259 positions worth $257M, down 4.9% from $271M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Alpha DNA Investment Management withdrew a net $15.3M in Q2 2024, closing 57 positions and reducing 68 holdings. Its most notable exit was Cigna, an estimated $2.32M position sold in full.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 17% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Alpha DNA Investment Management opened a new position in Colgate-Palmolive worth $2.32M.

  • Alpha DNA Investment Management's largest Q2 2024 buy was Colgate-Palmolive: 23,939 shares worth $2.32M.
  • Alpha DNA Investment Management added most to Wells Fargo in Q2 2024, an estimated $2.53M increase.
  • Alpha DNA Investment Management's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.62M.
  • Alpha DNA Investment Management fully exited Cigna in Q2 2024, selling an estimated $2.32M.
  • Alpha DNA Investment Management's ten largest holdings make up 43% of its $257M portfolio in Q2 2024.
  • Alpha DNA Investment Management opened 67 new positions and closed 57 in Q2 2024.
  • Alpha DNA Investment Management's portfolio value fell 4.9% quarter-over-quarter to $257M.

Based on Alpha DNA Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.